EI
The startup develops human cell-derived exosome therapies aimed at treating intractable diseases, focusing on complex pathological conditions that are resistant to conventional treatments. By leveraging exosome-based drug delivery systems, the company enhances therapeutic efficacy and patient outcomes in challenging medical scenarios.
Updated 3 months ago
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops human cell-derived exosome therapies aimed at treating intractable diseases, focusing on complex pathological conditions that are resistant to conventional treatments. By leveraging exosome-based drug delivery systems, the company enhances therapeutic efficacy and patient outcomes in challenging medical scenarios.